Saroglitazar was also found effective in lowering ALT [17, 18, 22] and improving fatty liver (evaluated by sonographic (FibroScanTM) investigation) in NAFLD patients with diabetic dyslipidemia [18]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.